Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection

Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced today that two oral presentations and a poster presentation featuring data for the company's NeXT Personal^® ultrasensitive ctDNA assay for residual and recurrent cancer detection will be presented at the American Association for Cancer Research (AACR) Annual Meeting April 25-30, 2025 in Chicago, Illinois.

"Our collaborators are excited to present new data, including initial results from the VICTORI study where NeXT Personal is being used to identify residual and recurrent colorectal cancer in patients. With a more sensitive test, our goal is to improve patient outcomes by finding and treating colorectal cancer recurrence earlier. We are also thrilled that NeXT Personal results from the TRACERx collaboration, one of the largest ctDNA studies in early-stage lung cancer, will be presented at the meeting," said Dr. Richard Chen, Chief Medical Officer and Executive Vice President, R&D at Personalis.

The two oral presentations are:

Oral Presentation: Detection of post-surgical minimal residual disease (MRD) in colorectal cancer; preliminary results from the VICTORI study

Time: April 28, 2025, 3:35 PM - 3:50 PM

Location: Room S105 - McCormick Place South (Level 1)

Presenter: Emma Titmuss, BC Cancer, Vancouver, BC, Canada

Oral Presentation: Ultrasensitive MRD detection: Results from TRACERx

Time: April 28, 2025, 12:35 PM - 12:55 PM

Location: Room S100 BC (Grand Ballroom BC) - McCormick Place South (Level 1)

Presenter: Charles Swanton, The Francis Crick Institute, London, United Kingdom

Additionally, a poster presentation detailing results from clinical NeXT Personal testing across >15 different cancer types will be presented:

Poster Presentation: Impact of an ultrasensitive ctDNA test on MRD detection in real world clinical patient testing

Time: April 29, 2025, 9:00 AM - 12:00 PM

Location: Section 29, poster 4549

Presenter: Rachel Marty Pyke, Personalis, Inc., Fremont, CA

About Personalis, Inc.

At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and X (Twitter).

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical are "forward-looking statements" within the meaning of U.S. securities laws, including statements relating to the attributes, advantages, sensitivity, clinical relevance or importance of the NeXT Personal test. Such forward-looking statements involve known and unknown risks and uncertainties and other factors that may cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements, including the risks, uncertainties and other factors that relate to the ability of NeXT Personal to detect small traces of ctDNA, detect residual or recurrent cancer early (including detection earlier than standard of care imaging), monitor a patient's response to therapy, accurately predict clinical outcomes for cancer patients, or impact cancer care or management (including for escalation or de-escalation of treatment), or to the clinical adoption or use of, or the ability of Personalis to obtain Medicare coverage or reimbursement for, the NeXT Personal test, or to the sufficiency of the publication and study results described in this press release to support such adoption, use, coverage or reimbursement. These and other potential risks and uncertainties that could cause actual results to differ materially from the results predicted in these forward-looking statements are described under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Personalis' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (SEC) on February 27, 2025. All information provided in this release is as of the date of this press release, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. Personalis undertakes no duty to update this information unless required by law.

Not affiliated with or endorsed by AACR.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250422948106/en/

Investors:

Caroline Corner

[email protected]

415-202-5678

Media Contact

[email protected]